Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for NEXIEN BIOPHARMA, INC. (NXEN : OTC)

• Company Description    Nexien BioPharma Inc. is a pharmaceutical development company. It engages in the formulation, development and commercialization of cannabinoid-based pharmaceuticals. Nexien BioPharma Inc., formerly known as Intiva BioPharma Inc., NY United States. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $0.05 Daily Weekly Monthly 20 Day Moving Average: 5,461 shares Shares Outstanding: 63.52 (millions) Market Capitalization: $3.02 (millions) Beta: 1.40 52 Week High: $0.10 52 Week Low: $0.02 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -3.06% -6.73% 12 Week 58.33% 46.98% Year To Date -19.22% -26.52%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4340 E Kentucky Ave. Suite 206 - Glendale,CO 80246 USA ph: 303-495-7583 fax: - rgreenberg@nexienbiopharma.com http://www.nexienbiopharma.com

• General Corporate Information    Officers Richard Greenberg - Chief Executive Officer and Chairman Robert I. Goldfarb - Chief Operating Officer Evan Wasoff - Chief Financial Officer Lindy Snider - Director Courtney Clark - director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 65343D100 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: 03/01/23 Next Expected EPS Date: 08/16/23 Share - Related Items Shares Outstanding: 63.52 Most Recent Split Date: 11.00 (0.17:1) Beta: 1.40 Market Capitalization: $3.02 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/16/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/23 - - 12/31/22 - - 09/30/22 - - ROA 03/31/23 - -400.86 12/31/22 - -419.50 09/30/22 - -600.27 Current Ratio 03/31/23 - 0.20 12/31/22 - 0.28 09/30/22 - 0.39 Quick Ratio 03/31/23 - 0.20 12/31/22 - 0.28 09/30/22 - 0.39 Operating Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Net Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Pre-Tax Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Book Value 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00 Inventory Turnover 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Equity 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Capital 03/31/23 - - 12/31/22 - - 09/30/22 - -

Powered by Zacks Investment Research ©